Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 71.4%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE (ORAL) vs QUETIAPINE

Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.62 [0.12, 3.07]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Relapse · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Clinically important change in life skills (long term) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Quality of life (long term) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.46 [0.05, 4.46]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Cost‐effectiveness · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found